{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:46:41Z","timestamp":1793832401376,"version":"4.6.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Hirt-Martin-Stiftung, Neuromuscular Research Association Basel"},{"DOI":"10.13039\/501100006390","name":"University of Lausanne","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006390","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Duchenne muscular dystrophy is life-limiting. Cardiomyopathy, which mostly ensues in the second decade of life, is the main cause of death. Treatment options are still limited. The TAMDMD (NCT03354039) trial assessed motor function, muscle strength and structure, laboratory biomarkers, and safety in 79 ambulant boys with genetically confirmed Duchenne muscular dystrophy, 6.5\u201312\u00a0years of age, receiving either daily tamoxifen 20\u00a0mg or placebo for 48\u00a0weeks. In this post-hoc analysis, available echocardiographic data of ambulant patients recruited at one study centre were retrieved and compared before and after treatment. Data from 14 patients, median 11 (interquartile range, IQR, 11\u201312) years of age was available. Baseline demographic characteristics were similar in participants assigned to placebo (<jats:italic>n<\/jats:italic>\u2009=\u20097) or tamoxifen (<jats:italic>n<\/jats:italic>\u2009=\u20097). Left ventricular end-diastolic diameter in the placebo group (median and IQR) was 39 (38\u201341) mm at baseline and 43 (38\u201344) mm at study end, while it was 44 (41\u201346) mm at baseline and 41 (37\u201346) mm after treatment in the tamoxifen group. Left ventricular fractional shortening in the placebo group was 35% (32\u201338%) before and 33% (32\u201336%) after treatment, while in the tamoxifen group it was 34% (33\u201334%) at baseline and 35% (33\u201335%) at study end. No safety signals were detected.<\/jats:p><jats:p><jats:italic>Conclusion<\/jats:italic>: This hypothesis-generating post-hoc analysis suggests that tamoxifen over 48\u00a0weeks is well tolerated and may help preserving cardiac structure and function in Duchenne muscular dystrophy. Further studies are justified.<\/jats:p><jats:p><jats:italic>ClinicalTrials.gov Identifier<\/jats:italic>: EudraCT 2017\u2013004554\u201342, NCT03354039<\/jats:p><jats:p><jats:table-wrap><jats:table><jats:tbody>\n                    <jats:tr>\n                      <jats:td align=\"left\"><jats:bold>What is known:<\/jats:bold><jats:italic>\u2022 Duchenne muscular dystrophy (DMD) is life-limiting. Cardiomyopathy ensues in the second decade of life and is the main cause of death. Treatment options are still limited.<\/jats:italic><jats:italic>\u2022 Tamoxifen reduced cardiac fibrosis in mice and improved cardiomyocyte function in human-induced pluripotent stem cell-derived cardiomyocytes.<\/jats:italic><\/jats:td>\n                    <\/jats:tr>\n                    <jats:tr>\n                      <jats:td align=\"left\"><jats:bold>What is new:<\/jats:bold><jats:italic>\u2022 In this post-hoc analysis of the TAMDMD trial among 14 boys, median 11\u00a0years of age, treated with either tamoxifen or placebo for 48\u00a0weeks, treatment was well-tolerated.<\/jats:italic><jats:italic>\u2022 A visual trend of improved left-ventricular dimensions and better systolic function preservation generates the hypothesis of a potential beneficial effect of tamoxifen in DMD cardiomyopathy.<\/jats:italic><\/jats:td>\n                    <\/jats:tr>\n                  <\/jats:tbody><\/jats:table><\/jats:table-wrap><\/jats:p>","DOI":"10.1007\/s00431-024-05670-9","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T22:04:44Z","timestamp":1720044284000},"page":"4057-4062","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Tamoxifen may contribute to preserve cardiac function in Duchenne muscular dystrophy"],"prefix":"10.1007","volume":"183","author":[{"given":"Bettina C.","family":"Henzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano A. G.","family":"Lava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Spagnuolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niveditha","family":"Putananickal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit C.","family":"Donner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pfluger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Burkhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,3]]},"reference":[{"issue":"4","key":"5670_CR1","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Alman BA, Apkon SD, Blackwell A et al (2018) Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol 17(4):347\u2013361","journal-title":"Lancet Neurol"},{"issue":"3","key":"5670_CR2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D et al (2018) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol 17(3):251\u2013267","journal-title":"Lancet Neurol"},{"issue":"5","key":"5670_CR3","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S1474-4422(18)30026-7","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Colvin MK et al (2018) Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan. Lancet Neurol 17(5):445\u2013455","journal-title":"Lancet Neurol"},{"issue":"4","key":"5670_CR4","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/S0960-8966(01)00303-0","volume":"12","author":"AE Emery","year":"2002","unstructured":"Emery AE (2002) Muscular dystrophy into the new millennium. Neuromuscular disorders NMD 12(4):343\u2013349","journal-title":"Neuromuscular disorders NMD"},{"issue":"10","key":"5670_CR5","first-page":"Cd009068","volume":"10","author":"JP Bourke","year":"2018","unstructured":"Bourke JP, Bueser T, Quinlivan R (2018) Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy. Cochrane Database Syst Rev 10(10):Cd009068","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"5670_CR6","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/S0960-8966(02)00140-2","volume":"12","author":"M Eagle","year":"2002","unstructured":"Eagle M, Baudouin SV, Chandler C, Giddings DR, Bullock R, Bushby K (2002) Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord 12(10):926\u2013929","journal-title":"Neuromuscul Disord"},{"issue":"5","key":"5670_CR7","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1097\/00019052-200310000-00003","volume":"16","author":"F Muntoni","year":"2003","unstructured":"Muntoni F (2003) Cardiomyopathy in muscular dystrophies. Curr Opin Neurol 16(5):577\u2013583","journal-title":"Curr Opin Neurol"},{"issue":"10","key":"5670_CR8","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.3390\/jcm9103186","volume":"9","author":"R Adorisio","year":"2020","unstructured":"Adorisio R, Mencarelli E, Cantarutti N, Calvieri C, Amato L, Cicenia M et al (2020) Duchenne dilated cardiomyopathy: cardiac management from prevention to advanced cardiovascular therapies. J Clin Med 9(10):3186","journal-title":"J Clin Med"},{"issue":"10","key":"5670_CR9","doi-asserted-by":"publisher","first-page":"e006340","DOI":"10.1161\/JAHA.117.006340","volume":"6","author":"D Cheeran","year":"2017","unstructured":"Cheeran D, Khan S, Khera R, Bhatt A, Garg S, Grodin JL et al (2017) Predictors of death in adults with Duchenne muscular dystrophy-associated cardiomyopathy. J Am Heart Assoc 6(10):e006340","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"5670_CR10","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.ajpath.2012.10.018","volume":"182","author":"OM Dorchies","year":"2013","unstructured":"Dorchies OM, Reutenauer-Patte J, Dahmane E, Ismail HM, Petermann O, Patthey- Vuadens O et al (2013) The anticancer drug tamoxifen counteracts the pathology in a mouse model of Duchenne muscular dystrophy. Am J Pathol 182(2):485\u2013504","journal-title":"Am J Pathol"},{"issue":"1","key":"5670_CR11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jpeds.2004.03.057","volume":"145","author":"SE Lawrence","year":"2004","unstructured":"Lawrence SE, Faught KA, Vethamuthu J, Lawson ML (2004) Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia. J Pediatr 145(1):71\u201376","journal-title":"J Pediatr"},{"issue":"1","key":"5670_CR12","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1186\/s13063-019-3740-6","volume":"20","author":"S Nagy","year":"2019","unstructured":"Nagy S, Hafner P, Schmidt S, Rubino-Nacht D, Sch\u00e4delin S, Bieri O et al (2019) Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial. Trials 20(1):637","journal-title":"Trials"},{"issue":"10","key":"5670_CR13","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/S1474-4422(23)00285-5","volume":"22","author":"BC Henzi","year":"2023","unstructured":"Henzi BC, Schmidt S, Nagy S, Rubino-Nacht D, Schaedelin S, Putananickal N et al (2023) Safety and efficacy of tamoxifen in boys with Duchenne muscular dystrophy (TAMDMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 22(10):890\u2013899","journal-title":"Lancet Neurol"},{"issue":"11","key":"5670_CR14","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/s41569-022-00717-6","volume":"19","author":"M Abdelsayed","year":"2022","unstructured":"Abdelsayed M, Kort EJ, Jovinge S, Mercola M (2022) Repurposing drugs to treat cardiovascular disease in the era of precision medicine. Nat Rev Cardiol 19(11):751\u2013764","journal-title":"Nat Rev Cardiol"},{"issue":"5","key":"5670_CR15","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.echo.2010.03.019","volume":"23","author":"L Lopez","year":"2010","unstructured":"Lopez L, Colan SD, Frommelt PC, Ensing GJ, Kendall K, Younoszai AK et al (2010) Recommendations for quantification methods during the performance of a pediatric echocardiogram: a report from the Pediatric Measurements Writing Group of the American Society of Echocardiography Pediatric and Congenital Heart Disease Council. J Am Soc Echocardiogr. 23(5):465\u201395 (quiz 576-7)","journal-title":"J Am Soc Echocardiogr."},{"issue":"6","key":"5670_CR16","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.cardfail.2012.03.001","volume":"18","author":"JW Rossano","year":"2012","unstructured":"Rossano JW, Kim JJ, Decker JA, Price JF, Zafar F, Graves DE et al (2012) Prevalence, morbidity, and mortality of heart failure-related hospitalizations in children in the United States: a population-based study. J Card Fail 18(6):459\u2013470","journal-title":"J Card Fail"},{"issue":"1","key":"5670_CR17","doi-asserted-by":"publisher","first-page":"323","DOI":"10.21037\/cdt-20-358","volume":"11","author":"H Ahmed","year":"2021","unstructured":"Ahmed H, VanderPluym C (2021) Medical management of pediatric heart failure. Cardiovasc Diagn Ther 11(1):323\u2013335","journal-title":"Cardiovasc Diagn Ther"},{"issue":"2","key":"5670_CR18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/ehf2.12082","volume":"3","author":"RE Andrews","year":"2016","unstructured":"Andrews RE, Fenton MJ, Dominguez T, Burch M (2016) Heart failure from heart muscle disease in childhood: a 5\u201310 year follow-up study in the UK and Ireland. ESC Heart Fail 3(2):107\u2013114","journal-title":"ESC Heart Fail"},{"issue":"5","key":"5670_CR19","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s00431-022-04768-2","volume":"182","author":"SAG Lava","year":"2023","unstructured":"Lava SAG, Zollinger C, Chehade H, Schaffner D, Sekarski N, Di Bernardo S (2023) Diuretics in pediatrics. Eur J Pediatr 182(5):2077\u20132088","journal-title":"Eur J Pediatr"},{"issue":"3","key":"5670_CR20","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s00431-023-05196-6","volume":"183","author":"F Sperotto","year":"2023","unstructured":"Sperotto F, L\u00f3pez Guill\u00e9n JL, Milani GP, Lava SAG (2023) Advances in pediatric cardiology. Eur J Pediatr 183(3):983\u2013985","journal-title":"Eur J Pediatr"},{"issue":"8","key":"5670_CR21","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.echo.2015.03.003","volume":"28","author":"CF Spurney","year":"2015","unstructured":"Spurney CF, McCaffrey FM, Cnaan A, Morgenroth LP, Ghelani SJ, Gordish-Dressman H et al (2015) Feasibility and reproducibility of echocardiographic measures in children with muscular dystrophies. J Am Soc Echocardiogr 28(8):999\u20131008","journal-title":"J Am Soc Echocardiogr"},{"key":"5670_CR22","doi-asserted-by":"crossref","unstructured":"Bourke J, Turner C, Bradlow W, Chikermane A, Coats C, Fenton M et al (2022) Cardiac care of children with dystrophinopathy and females carrying DMD-gene variations. Open Heart 9(2):e001977","DOI":"10.1136\/openhrt-2022-001977"},{"issue":"1","key":"5670_CR23","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1161\/CIRCIMAGING.110.960740","volume":"4","author":"D Verhaert","year":"2011","unstructured":"Verhaert D, Richards K, Rafael-Fortney JA, Raman SV (2011) Cardiac involvement in patients with muscular dystrophies: magnetic resonance imaging phenotype and genotypic considerations. Circ Cardiovasc Imaging 4(1):67\u201376","journal-title":"Circ Cardiovasc Imaging"},{"issue":"11","key":"5670_CR24","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1136\/jnnp-2019-320879","volume":"90","author":"AE Clout","year":"2019","unstructured":"Clout AE, Della Pasqua O, Hanna MG, Orlu M, Pitceathly RDS (2019) Drug repurposing in neurological diseases: an integrated approach to reduce trial and error. J Neurol Neurosurg Psychiatry 90(11):1270\u20131275","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"5670_CR25","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00431-016-2700-3","volume":"175","author":"D Schranz","year":"2016","unstructured":"Schranz D, Voelkel NF (2016) \u201cNihilism\u201d of chronic heart failure therapy in children and why effective therapy is withheld. Eur J Pediatr 175(4):445\u2013455","journal-title":"Eur J Pediatr"},{"issue":"1","key":"5670_CR26","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41536-022-00214-x","volume":"7","author":"F Birnbaum","year":"2022","unstructured":"Birnbaum F, Eguchi A, Pardon G, Chang ACY, Blau HM (2022) Tamoxifen treatment ameliorates contractile dysfunction of Duchenne muscular dystrophy stem cell-derived cardiomyocytes on bioengineered substrates. NPJ Regen Med 7(1):19","journal-title":"NPJ Regen Med"},{"issue":"3","key":"5670_CR27","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0009-9236(97)90160-0","volume":"61","author":"LB Sheiner","year":"1997","unstructured":"Sheiner LB (1997) Learning versus confirming in clinical drug development. Clin Pharmacol Ther 61(3):275\u2013291","journal-title":"Clin Pharmacol Ther"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-024-05670-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-024-05670-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-024-05670-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T10:09:05Z","timestamp":1723543745000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-024-05670-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,3]]},"references-count":27,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["5670"],"URL":"https:\/\/doi.org\/10.1007\/s00431-024-05670-9","relation":{},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,3]]},"assertion":[{"value":"31 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial was reviewed and approved by the ethics committee of both Basel cantons (2017\u201301708) and Swissmedic (2018DR3068). The project was conducted in accordance with the Declaration of Helsinki of 1964 and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from participants or their legal representatives (parents\/caregivers).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors gave their consent for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}